Physician profile
Ashlee M Graham
NPI 1144291303
$7,077.59
in general payments reported to CMS, 2019-2025
26 companies · $1,494 in 2025
The $1,494 reported for 2025 was more than what 85% of Psychiatric/Mental Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $244).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,370 · 2022: $1,282 · 2023: $1,360 · 2024: $1,572 · 2025: $1,494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,425.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $894.86 | 2021-2025 | Caplyta |
| Corium, LLC | $861.98 | 2021-2025 | Azstarys |
| Abbvie INC. | $780.67 | 2021-2025 | |
| Alkermes, INC. | $537.56 | 2021-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $521.09 | 2021-2025 | Rexulti |
| Lundbeck LLC | $517.28 | 2021-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $480.23 | 2021-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $399.96 | 2021-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $382.44 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $357.98 | 2022-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $319.93 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $312.25 | 2021-2024 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $191.29 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $130.25 | 2024-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $68.45 | 2025 | Cobenfy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $64.76 | 2024 | Loreev Xr |
| Janssen Pharmaceuticals, INC | $64.41 | 2022-2024 | Spravato |
| Collegium Pharmaceutical, INC. | $61.49 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $27.85 | 2022 | |
| Allergan, INC. | $17.58 | 2021 | |
| Sage Therapeutics, LLC | $15.68 | 2024 | |
| Sun Pharmaceutical Industries INC. | $14.63 | 2021 | |
| Adlon Therapeutics L.P. | $14.57 | 2021 | |
| Jazz Pharmaceuticals INC. | $14.25 | 2021 | |
| Eisai INC. | $13.30 | 2021 | |
| Avanir Pharmaceuticals, INC. | $12.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashlee Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.